ABOT · Abbott Laboratories (Pakistan) Limited
Abbott Laboratories Pakistan Financial Results Nine Months 2026
Official PSX filing title: Financial Results for the Quarter Ended September 30, 2026
- Filed
- 27 October 2026 at 1:08 pm
- Category
- Financials
- Sentiment
- Good
- Impact
- High
Executive summary
Abbott Laboratories (Pakistan) Limited reported a strong performance for the nine months ended September 30, 2026, with net profit after tax rising to PKR 6,684.18 million compared to PKR 5,365.71 million in the same period last year. Basic and diluted EPS improved to PKR 68.28 from PKR 54.81.
Key takeaways
- Net profit after tax for the nine months ended September 30, 2026, rose 24.6% YoY to PKR 6,684.18 million from PKR 5,365.71 million.
- Basic and diluted earnings per share (EPS) increased to PKR 68.28 for the nine-month period compared to PKR 54.81 previously.
- Net sales for the nine months grew to PKR 58,656.29 million from PKR 56,226.92 million in the comparative period.
- Profit before taxation for the nine months reached PKR 11,402.47 million compared to PKR 9,158.22 million a year ago.
- Standalone quarterly net profit for the three months ended September 30, 2026, stood at PKR 2,543.95 million with an EPS of PKR 25.99.
Filing details
Financial results
Quarterly · Unaudited · Standalone · 30 September 2026
Figures in PKR '000
Reporting period
Nine Months
- Income
- 58,656,293 (prior 56,226,923)
- Profit after tax
- 6,684,182 (prior 5,365,718)
- EPS
- 68.28 (prior 54.81)
Quarter
Three Months
- Income
- 20,629,742 (prior 19,819,134)
- Profit after tax
- 2,543,951 (prior 1,822,546)
- EPS
- 25.99 (prior 18.62)
Dividend and entitlement
- Type
- None
- Notes
- No cash dividend, bonus, or rights entitlement declared (all entries stated as NIL).
- #abot
- #financial-results
- #earnings
- #pharma
Please cross-check with the official PSX filing before making an investment decision.